The improved health utility of once-weekly subcutaneous semaglutide 2.4 mg compared with placebo in the STEP 1-4 obesity trials.

Jakob Bue Bjorner,Sara Larsen,Christopher Lübker,Thomas Holst-Hansen

Diabetes, obesity & metabolism（2023）

引用 0|浏览8

暂无评分

摘要

Semaglutide 2.4 mg was associated with improvement in health utility scores compared with placebo, reaching statistical significance in STEP 1, 2 and 4. This article is protected by copyright. All rights reserved.

查看译文

关键词

antiobesity drug, patient-reported outcomes, pharmaco-economics, randomized trial

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要